JARDIANCE provides patients the convenience of a once-daily oral dose
- The 10 mg starting dose of JARDIANCE provides glycemic control and CV death risk reduction in adult T2D patients who also have established CVD¹
- In patients who tolerate JARDIANCE 10 mg, the dose can be increased to 25 mg once daily
- No fasting requirements before or after taking JARDIANCE
- In patients with volume depletion, correcting this condition prior to initiation of JARDIANCE is recommended
- A lower dose of insulin or insulin secretagogues (eg, sulfonylureas) may be required to reduce the risk of hypoglycemia when JARDIANCE is used in combination with these agents
- JARDIANCE is contraindicated in patients with a history of serious hypersensitivity to empagliflozin or any of the excipients in JARDIANCE; severe renal impairment, end-stage renal disease, or dialysis
- Dosing in patients with renal impairment:
- Glycemic efficacy of JARDIANCE is dependent on renal function, which should be assessed prior to initiation of JARDIANCE and periodically thereafter
- Should not be initiated if eGFR is <45 mL/min/1.73 m²
- Should be discontinued if eGFR is persistently <45 mL/min/1.73 m²
- Reduction in risk of CV death was consistently observed among patients, including those with eGFR <60 mL/min/1.73 m²
More patients have access to JARDIANCE than all DPP-4 inhibitors or SGLT2 inhibitors across Commercial and Medicare Part D*
More coverage may mean fewer callbacks
Help your patients save with the JARDIANCE co-pay card
Eligible patients can pay as little as $10† per prescription for an entire year—and then re-enroll for another 12 months of savings after that, as long as they still qualify.
- † See Terms and Conditions. Medicare/Medicaid/cash-paying patients excluded from Savings Card enrollment.
CV=cardiovascular; CVD=cardiovascular disease; DPP-4=dipeptidyl peptidase-4; eGFR=estimated glomerular filtration rate; SGLT2=sodium glucose co-transporter-2; T2D=type 2 diabetes.